ARTICLE | Clinical News
Botox botulinum toxin: Phase III data
September 15, 2008 7:00 AM UTC
Top-line data from a double-blind, placebo-controlled Phase III trial in 705 patients showed that Botox met the primary endpoint of a significant decrease in number of headache days vs. placebo (p<0.0...